Anti-tumor efficacy of the molecules was tested in several mouse models of human cancer including BT474 and SKOV3 (ovarian) both of which contain PIK3CA mutations (H1047R or K111N) and amplification of ERBB2 rendering the AKT pathway hyperactive. This evidence concerns the gene ERBB2 and cancer.